Literature DB >> 3277515

Pulmonary hypertension from chronic pulmonary thromboembolism.

S Rich1, S Levitsky, B H Brundage.   

Abstract

Pulmonary hypertension may develop whenever chronic obstruction of pulmonary arterial blood flow occurs. Although repeated pulmonary embolism is thought to be the usual underlying cause, there is little clinical evidence to support this theory. Studies of the pulmonary vascular endothelium have shown that perturbations of the normal endothelium can create a procoagulant environment, which could lead to the development of thrombosis in situ at the level of the large or smaller pulmonary vessels. Some patients develop proximal pulmonary thromboemboli, which may be the result of retrograde propagation of thrombus after an initial pulmonary embolus. Others present with unexplained pulmonary hypertension secondary to thrombotic occlusion of the pulmonary microvasculature. A perfusion lung scan will show abnormalities that should lead to correct clinical diagnosis and confirmatory evaluation. Thromboendarterectomy in selected cases provides dramatic clinical improvement in patients with proximal thromboemboli. Vasodilators may be effective in some patients with obstruction at the arteriolar level. Both groups should be treated with chronic warfarin anticoagulant therapy to protect against progression of thromboembolism.

Entities:  

Mesh:

Year:  1988        PMID: 3277515     DOI: 10.7326/0003-4819-108-3-425

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  10 in total

1.  Chronic Thromboembolic Pulmonary Hypertension.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-04

Review 2.  Ultrafast CT and the cardiovascular system.

Authors:  M S Bleiweis; D Georgiou; B H Brundage
Journal:  Int J Card Imaging       Date:  1992

3.  Pulmonary hypertension in patients with chronic pulmonary thromboembolism: chest radiograph and CT evaluation before and after surgery.

Authors:  H C Schmidt; H U Kauczor; H H Schild; C Renner; E Kirchhoff; P Lang; S Iversen; M Thelen
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

4.  Value of contrast-enhanced MR angiography and helical CT angiography in chronic thromboembolic pulmonary hypertension.

Authors:  Sebastian Ley; Hans-Ulrich Kauczor; Claus Peter Heussel; Thorsten Kramm; Eckhard Mayer; Manfred Thelen; Karl-Friedrich Kreitner
Journal:  Eur Radiol       Date:  2003-04-24       Impact factor: 5.315

5.  Are pulmonary artery pulsatility indexes able to differentiate chronic pulmonary thromboembolism from pulmonary arterial hypertension? An echocardiographic and catheterization study.

Authors:  Tomas Palecek; Pavel Jansa; David Ambroz; Zuzana Hlubocka; Jan Horak; Marcela Skvarilova; Michael Aschermann; Ales Linhart
Journal:  Heart Vessels       Date:  2010-10-16       Impact factor: 2.037

Review 6.  New approaches to the treatment of pulmonary hypertension: from bench to bedside.

Authors:  Subramanyam N Murthy; Bobby D Nossaman; Philip J Kadowitz
Journal:  Cardiol Rev       Date:  2010 Mar-Apr       Impact factor: 2.644

7.  Successful pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension associated with anticardiolipin antibodies: report of a case.

Authors:  Y Nakagawa; M Masuda; H Shiihara; Y Tsuruta; H Abe; M Miura; H Tanaka
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

8.  Indications for thrombolytic therapy in acute pulmonary embolism.

Authors:  J A Dieck; J J Ferguson
Journal:  Tex Heart Inst J       Date:  1989

9.  Clinical implications of the morphological features of central pulmonary artery thromboemboli shown by transoesophageal echocardiography.

Authors:  R K Chan; J A Johns; P Calafiore
Journal:  Br Heart J       Date:  1994-07

10.  Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders.

Authors:  Vichai Atichartakarn; Khanchit Likittanasombat; Suporn Chuncharunee; Pakorn Chandanamattha; Surapon Worapongpaiboon; Pantep Angchaisuksiri; Katcharin Aryurachai
Journal:  Int J Hematol       Date:  2003-08       Impact factor: 2.490

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.